Background: Leiomyosarcoma are malignant tumours of the soft tissues. It is most commonly found in the stomach, small intestine and retroperitoneum. Primary pancreatic leiomyosarcoma is extremely rare and only 22 cases have been reported in the literature since 1951. Its prognosis is poor and the palliative treatment is only aimed at symptomatic improvement.
Background
The incidence rate for pancreatic cancer is approximately nine new cases per 100,000 people, with the peak incidence in the seventh and eighth decades of life and an average age of 60 to 65 years at diagnosis [1] . The commonest type is an adenocarcinoma.
Primary pancreatic leiomyosarcoma is a rare malignant neoplasm. It accounts for 0.1% of malignant pancreatic cancers [1] . A review of the literature reveals 22 such cases published so far [2] . The majority of the reported cases were diagnosed on autopsy.
Survival in patients with untreated PC is poor. For all stages combined, the 1-year survival rate is 19% and the 5-year survival rate is 4% [1] . The majority (80%) of PCs are metastatic at the time of diagnosis. Surgical resection (when margin negative, node negative) offers the best possibility for cure, with 5-year survival approaching 40% when performed at specialized major medical institutions [3] .
We report a case of Primary leiomyosarcoma of Pancreas occurring in a 73 years old male.
Case presentation
A 73 years old male presented with 1 month history of weight loss of 16 kilograms, epigastric pain, anorexia, abdominal fullness and jaundice. He was recently diagnosed with diabetes mellitus. Liver was palpable on examination of his abdomen. He had a raised bilirubin and liver enzymes. Abdominal ultrasound & CT scan demon-strated an enlarged liver containing multiple irregular ill defined lesions including the caudate lobe suggestive of metastases. There was a large enhancing soft tissue mass with a central necrotic area approximately measuring 9.4 × 10 cms in the region of the body of pancreas. This mass was compressing splenic artery and vein. The patient underwent Ultrasound guided liver biopsy. Histological & Immunohistochemical analysis confirmed leiomyosarcoma of the pancreatic origin. This case was discussed in relevant multidisciplinary team meeting. As his disease was already in advanced metastatic phase so he was offered palliative chemotherapy. His condition deteriorated before the chemotherapy & he died after 3 months of the initial diagnosis. No autopsy was conducted.
Histological examination was suggestive of Spindle cell neoplasm (Figures 1 &2) . The spindle cells showed mild to moderate nuclear pleomorphism & anisocytosis. There was generally less than 1 mitotic figure per high power field & no abnormal mitotic figures were seen. The spindle cells were positive for desmin & smooth muscle actin. These were negative for cytokeratin (AE1/AE3), HMB45, S100 protein, melanin A, NSE (neuron specific enolase), CD34 and CD 117. The immune profile was suggestive of leiomyosarcoma.
In conclusion, the histological & Immunohistochemical features of the tumour were consistent with low to intermediate grade leiomyosarcoma.
Discussion
Primary pancreatic leiomyosarcoma is a rare malignant neoplasm reported in world literature by only 22 cases up to this time.
We report a case of primary pancreatic leiomyosarcoma. This tumour was involving the body of the pancreas with direct invasion of the splenic vessels along with multiple hepatic secondaries. Complete clinical and radiological evaluation excluded secondary pancreatic involvement by a sarcoma of the retroperitoneal and gastrointestinal origin. Immunohistochemical analysis of the samples confirmed this tumour as a smooth muscle sarcoma.
Leiomyosarcomas involving pancreas consist of primary pancreatic leiomyosarcoma or pancreatic extensions of retroperitoneal and gastro-duodenal sarcomas [2] . Pancreatic mesenchymal tumours consist of malignant peripheral nerve sheath tumours, malignant fibrous histiocytomas, liposarcomas, rhabdomyosarcomas, hemipericytomas & leiomyosarcomas [3] . A detailed clinical evaluation is essential to rule out a primary extra pancreatic leiomyosarcomas. Female genital tract, gastrointestinal tract, soft tissues of the extremities and retroperitoneum are the most commonly affected areas [2] . Table 1 summarizes the clinicopathological data of the 22 reported cases of pancreatic leiomyosarcoma. Abdominal pain, weight loss, epigastric tenderness & abdominal mass are the most commonly presenting symptoms [4] . Pancreatic leiomyosarcoma is more common in fifth decade of life or older (mean age 44.7 years; range 14 to 80 years). Males are affected almost twice as compared to females (7:4). The size of the tumours is quite variable ranging from 3 cm to 25 cm (Median,10.5 cm). It is observed that larger tumour can develop cystic degeneration & can be misdiagnosed as pseudocysts of pancreas [4] .
In the documented literature, about 43.5% (10 patients) presented with locally advanced or metastatic disease.
First ever case of pancreatic leiomyosarcoma was diagnosed on autopsy [5] . Three patients died at 3,9 and 33 months respectively after the diagnosis [6, 7] . We do not know precisely about the survival outcome of remaining 6 patients.
At the time of diagnosis of leiomyosarcoma, only 13 cases seem to be localised to pancreas & underwent surgical [6, 8, 9] . Remaining 4 patients were alive & free of symptoms at 1,3,4,6 years after the initial surgical management [10] [11] [12] .
Large tumour size is not a precise predictor of adverse outcome. In leiomyomatous tumours mitotic figures are proposed to present the important predicting parameter [13] . Mitotic counts of more than 10 mitoses/10 HPFs is associated with a worse outcome [2] .
Conclusion
The number of cases of pancreatic leiomyosarcoma reported in world literature is limited but what we have learnt that it is a highly malignant tumour which can be metastatic even on first presentation. Extensive surgical resection of tumour is still the best treatment option for localised disease. Metastatic pancreatic leiomyosarcomas have shown only a partial response to chemotherapy.
Treatment is aimed at symptomatic improvement and pain management.
Consent
Written informed consent could not be obtained since the patient is deceased and the next of kin were untraceable. We believe this case report contains a worthwhile clinical lesson which could not be as effectively made in any other way. We expect that the next of kin would not object to the publication since the patient remains anonymous.
